Apellis Pharmaceuticals Inc. (APLS) saw its stock price plummet 5.02% in pre-market trading on Friday, following a wave of analyst downgrades and price target cuts. The biotechnology company, which focuses on the development of novel therapeutic compounds, faced a significant setback as several prominent financial institutions revised their outlook on the stock.

The negative sentiment was primarily driven by a series of analyst actions. TD Cowen reduced its price target for Apellis from $50 to $45, while Morgan Stanley maintained a Hold rating with a lowered price target of $25.00. Wells Fargo also joined the bearish trend, cutting its target from $32 to $29. RBC Capital reiterated its Hold rating with a price target of $22.00, further contributing to the downward pressure on the stock.

Despite the overall negative sentiment, not all analysts were entirely pessimistic. H.C. Wainwright, while lowering its price target from $57 to $45, maintained a Buy rating on the stock. Similarly, Raymond James adjusted its target price to $45 from $50. These mixed signals suggest that while there are concerns about Apellis' near-term performance, some analysts still see potential in the company's long-term prospects. Investors will likely be closely monitoring Apellis' upcoming announcements and clinical trial results to gauge the company's future trajectory in the competitive biotechnology sector.